semaglutide news october 16 2025 The FDA has approved Wegovy (semaglutide) as a treatment for metabolic-associated steatohepatitis (MASH) with moderate-to-advanced scarring, a serious liver condition affecting approximately 6% of US adults. Key highlights of drug development program semaglutide news october 16 2025

Comprehensive cardiovascular risk management remains paramount for patients with type 2 diabetes receiving tirzepatide therapy, as diabetes increases cardiovascular risk

GLP-1s also provide several other important health benefits: Better blood sugar control: This is especially helpful for people with prediabetes, as it may prevent progression to type 2 diabetes

However, other methods (such as injection) can be considered more effective due to direct delivery

Studies tell us that, mechanistically, semaglutide works to: Reduce appetite and hunger signaling Steady blood sugar Slow the rate at which your food out of your stomach and into your small intestine, making you feel fuller longer All of which assist with changing your behaviors such that you consume fewer calories over time

While oral forms of semaglutide currently show less total weight loss than injectables in clinical trials, the improved absorption of sublingual drops makes them a powerful and viable option for many individuals